|2nd November 2020||Adam K Stern||619||Open or private purchase||$0.00|
|2nd October 2020||Adam K Stern||619||Open or private purchase||$0.00|
|30th September 2020||Matthew Wikler||20,725||Grant/award etc.||$0.00|
|17th September 2020||Eric J Ende||17,000||Open or private purchase||$5.79||$98,375.60|
|3rd September 2020||Adam K Stern||639||Open or private purchase||$6.66||$4,255.74|
|1st September 2020||Patrick G Lepore||38,986||Grant/award etc.||$0.00|
|21st August 2020||Adam K Stern||20,000||Open or private purchase||$0.83||$16,600.00|
|13th August 2020||Eric J Ende||1,200||Open or private purchase||$7.74||$9,288.00|
|13th August 2020||Eric J Ende||3,800||Open or private purchase||$7.80||$29,640.00|
|12th August 2020||Eric J Ende||15,000||Open or private purchase||$7.76||$116,355.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B. The company was founded in May 2013 and is headquartered in Bedminster, NJ.